Cerus Corporation announced a four‑year supply agreement with the French Blood Establishment (Etablissement Francais du Sang, EFS) that will deliver the company’s INTERCEPT Blood System for platelets and plasma, as well as the INT200 illumination device, to the national blood provider. The contract covers a steady stream of product deliveries to a customer that distributes roughly 330,000 platelet units each year and has used INTERCEPT technology since 2006, with nationwide adoption following a 2017 rollout.
The deal comes on the heels of Cerus’s 2025 financial results, in which the company reported record total revenue of $233.8 million, a 16% increase from 2024, and a 14% rise in product revenue for both the quarter and the year. The company also posted a GAAP net loss of $15.6 million, a 25% improvement over the prior year, and achieved a second consecutive year of positive adjusted EBITDA of $9.5 million. The new supply agreement is positioned to support continued revenue growth and reinforce the company’s market share in a key European region.
Christian Boutemy, Cerus’s vice president of international commercial operations, said, "EFS has been a global leader in the adoption of pathogen inactivation technologies to help safeguard the blood supply and enhance patient safety." The quote underscores the strategic importance of the partnership and signals Cerus’s confidence in the long‑term value of its technology in a market that has historically trusted its products.
The agreement strengthens Cerus’s foothold in France, a country that has relied on INTERCEPT for over a decade, and expands the company’s product portfolio with the addition of the INT200 illumination device. While the deal is a positive development, Cerus continues to face inflationary pressures and tariff‑related cost increases that have compressed product gross margins from 53.9% to 51.5% in the most recent quarter. The company’s management has indicated that it is monitoring these headwinds closely while pursuing opportunities to leverage its established relationships and technology leadership in the blood safety market.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.